A Phase 1 interventional study of Herceptin in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-16.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 170th largest by enrollment of the 366 interventional ones that give a count, is one of 14 that started in 2008, is one of 21 in phase 1, and was the 129th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 14 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 125th largest by enrollment of the 170 interventional ones that give a count, is one of 11 that started in 2008, is one of 27 in phase 1, and was the 43rd registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This two-part study is designed to select the subcutaneous (SC) dose of Herceptin that results in comparable exposure to intravenous (IV) Herceptin in healthy male participants and in HER2-positive female participants. The study will also assess the safety and tolerability of the SC and IV formulations. In Part 1 of the study, four cohorts will be treated with a single dose of Herceptin as follows: Cohort 1 (6 milligrams per kilogram [mg/kg] IV in healthy male participants); Cohort 2 (6 mg/kg IV in HER2-positive female participants); Cohort 3 (6 mg/kg SC in healthy male participants); Cohort 4 (10 mg/kg SC in healthy male participants). An additional cohort of healthy volunteers (Cohort 5) will be opened if both SC dose levels from Cohorts 3 and 4 result in Herceptin exposures different from the target concentration produced by a single IV dose, or if the variability in pharmacokinetic (PK) parameter values cannot be used to define the target SC dose level. In Part 2 of the study, HER2-positive female participants will receive a single dose of SC Herceptin at the dose level defined in Part 1. Participants from Part 1 are eligible to enter Part 2 provided they receive the second (Part 2) study dose of Herceptin a minimum of 22 days after their first (Part 1) dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy Participants (Part 1 only)
-Positive Females (Parts 1 and 2)
Exclusion Criteria:
Healthy Participants (Part 1 only)
-Positive Females (Parts 1 and 2)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male participants will receive Herceptin 6 mg/kg IV on Day 1.
Drug: Herceptin
Female participants with HER2-positive breast cancer will receive Herceptin 6 mg/kg IV on Day 1.
Drug: Herceptin
Healthy male participants will receive Herceptin 6 mg/kg SC on Day 1.
Drug: Herceptin
Healthy male participants will receive Herceptin 10 mg/kg SC on Day 1.
Drug: Herceptin
Healthy male participants will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohorts 1, 2, 3, and 4.
Drug: Herceptin
Female participants with HER2-positive breast cancer will receive Herceptin SC at the dose level determined in Part 1.
Drug: Herceptin
Female participants with HER2-positive breast cancer will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohort A.
Drug: Herceptin
Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
Also known as: Trastuzumab
Area Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Trastuzumab
AUCinf represents the area under the concentration-time curve of trastuzumab in serum over the time interval from 0 extrapolated to infinity. Values for AUCinf of trastuzumab were derived by non-compartmental analysis across all pharmacokinetic (PK) collections and expressed in days by micrograms per milliliter (days•μg/mL).
Time frame: Predose (0 hours) and postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)
Trough Serum Concentration on Day 22 (CDay22) of Trastuzumab
CDay22 of trastuzumab was derived from the single PK collection on Day 22 and expressed in micrograms per milliliter (μg/mL).
Time frame: Day 22
Maximum Observed Serum Concentration of Trastuzumab (Cmax)
Cmax of trastuzumab was derived across all post-dose PK collections and expressed in μg/mL.
Time frame: Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)
Time to Maximum Serum Concentration (Tmax) of Trastuzumab
Tmax of trastuzumab was based on the Cmax derived across all post-dose PK collections and expressed in hours.
Time frame: Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)
Terminal Elimination Half-Life (T1/2) of Trastuzumab
T1/2 of trastuzumab was measured as the time required for trastuzumab concentration to decrease by one-half. T1/2 was derived across all PK collections and expressed in hours.
Time frame: Postdose from start of 1.5-hour infusion (1.5 and 3 hours for IV) (6, 8, 12 hours for SC) on Day 1; on Days 2, 3, 5, 8, 15, 22, 43, 85; additionally on Day 10 for SC and Day 35 for IV; and 5 months postdose (up to 5 months overall)
| Milestone | Part 1: Cohort 1 | Part 1: Cohort 2 | Part 1: Cohort 3 | Part 1: Cohort 4 | Part 1: Cohort 5 | Part 2: Cohort A | Part 2: Cohort B |
|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 20 | 20 |
| Completed | 6 | 6 | 5 | 5 | 6 | 20 | 20 |
| Not completed | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
AUCinf represents the area under the concentration-time curve of trastuzumab in serum over the time interval from 0 extrapolated to infinity. Values for AUCinf of trastuzumab were derived by non-compartmental analysis across all pharmacokinetic (PK) collections and expressed in days by micrograms per milliliter (days•μg/mL).
| days•μg/mL | Part 1: Cohort 1 | Part 1: Cohort 2 | Part 1: Cohort 3 | Part 1: Cohort 4 | Part 1: Cohort 5 | Part 2: Cohort A | Part 2: Cohort B |
|---|---|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Trastuzumab | 1610 ± 303 | 1800 ± 250 | 1350 ± 320 | 2500 ± 515 | 1960 ± 244 | 2090 ± 638 | 3550 ± 982 |
CDay22 of trastuzumab was derived from the single PK collection on Day 22 and expressed in micrograms per milliliter (μg/mL).
| μg/mL | Part 1: Cohort 1 | Part 1: Cohort 2 | Part 1: Cohort 3 | Part 1: Cohort 4 | Part 1: Cohort 5 | Part 2: Cohort A | Part 2: Cohort B |
|---|---|---|---|---|---|---|---|
| Trough Serum Concentration on Day 22 (CDay22) of Trastuzumab | 25.6 ± 12.1 | 27.5 ± 7.5 | 31.6 ± 12.0 | 51.4 ± 15.8 | 39.4 ± 5.5 | 37.8 ± 10.4 | 60.8 ± 22.0 |
Cmax of trastuzumab was derived across all post-dose PK collections and expressed in μg/mL.
| μg/mL | Part 1: Cohort 1 | Part 1: Cohort 2 | Part 1: Cohort 3 | Part 1: Cohort 4 | Part 1: Cohort 5 | Part 2: Cohort A | Part 2: Cohort B |
|---|---|---|---|---|---|---|---|
| Maximum Observed Serum Concentration of Trastuzumab (Cmax) | 150 ± 14.4 | 185 ± 42.9 | 66.8 ± 11.4 | 102 ± 17.2 | 82.0 ± 11.3 | 88.4 ± 33.3 | 151 ± 58.6 |
Tmax of trastuzumab was based on the Cmax derived across all post-dose PK collections and expressed in hours.
| hours | Part 1: Cohort 1 | Part 1: Cohort 2 | Part 1: Cohort 3 | Part 1: Cohort 4 | Part 1: Cohort 5 | Part 2: Cohort A | Part 2: Cohort B |
|---|---|---|---|---|---|---|---|
| Time to Maximum Serum Concentration (Tmax) of Trastuzumab | 1.65 (1.6 to 24.0) | 3.00 (1.55 to 24.0) | 156.00 (95.95 to 216.10) | 132.12 (96.00 to 216.00) | 96.00 (96.00 to 215.98) | 97.13 (47.93 to 216.60) | 96.05 (24.53 to 241.40) |
T1/2 of trastuzumab was measured as the time required for trastuzumab concentration to decrease by one-half. T1/2 was derived across all PK collections and expressed in hours.
| hours | Part 1: Cohort 1 | Part 1: Cohort 2 | Part 1: Cohort 3 | Part 1: Cohort 4 | Part 1: Cohort 5 | Part 2: Cohort A | Part 2: Cohort B |
|---|---|---|---|---|---|---|---|
| Terminal Elimination Half-Life (T1/2) of Trastuzumab | 254 ± 32.2 | 244 ± 69.2 | 227 ± 55.9 | 240 ± 34.4 | 236 ± 43.9 | 241 ± 48.1 | 270 ± 80.1 |
Collected over From Baseline up to 5 months post-dose (up to 5 months overall). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Cohort 1 | — | 0/6 (0%) | 5/6 (83.3%) |
| Part 1: Cohort 2 | — | 0/6 (0%) | 6/6 (100%) |
| Part 1: Cohort 3 | — | 0/6 (0%) | 5/6 (83.3%) |
| Part 1: Cohort 4 | — | 0/6 (0%) | 5/6 (83.3%) |
| Part 1: Cohort 5 | — | 0/6 (0%) | 6/6 (100%) |
| Part 2: Cohort A | — | 0/20 (0%) | 19/20 (95%) |
| Part 2: Cohort B | — | 0/20 (0%) | 20/20 (100%) |
| Event | Part 1: Cohort 1 | Part 1: Cohort 2 | Part 1: Cohort 3 | Part 1: Cohort 4 | Part 1: Cohort 5 | Part 2: Cohort A | Part 2: Cohort B |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/6 | 2/6 | 2/6 | 0/6 | 2/6 | 12/20 | 14/20 |
| Injection site discolourationGeneral disorders | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 3/20 | 0/20 |
| Infusion related reactionGeneral disorders | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/20 | 0/20 |
| Upper respiratory tract InfectionInfections and infestations | 0/6 | 0/6 | 1/6 | 2/6 | 1/6 | 4/20 | 5/20 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 2/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/20 | 1/20 |
| DiarrhoeaGastrointestinal disorders | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 6/20 | 2/20 |
| Abdominal painGastrointestinal disorders | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/20 | 0/20 |
| AcneSkin and subcutaneous tissue disorders | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 | 0/20 | 0/20 |
| Injection site erythemaGeneral disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 4/20 | 2/20 |
| LethargyNervous system disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 4/20 | 2/20 |
Safety Population: All participants who received at least one dose of study medication, whether prematurely withdrawn from the study or not. The "Total" column (n=70) includes 4 female participants who were counted twice as they were treated in both Cohort 2 and Cohort A.
| Age, Continuous(years) | Part 1: Cohort 1 | Part 1: Cohort 2 | Part 1: Cohort 3 | Part 1: Cohort 4 | Part 1: Cohort 5 | Part 2: Cohort A | Part 2: Cohort B | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 22.7 ± 2.58 | 46.2 ± 5.19 | 25.7 ± 9.29 | 23.0 ± 6.16 | 22.0 ± 4.34 | 50.7 ± 7.21 | 51.6 ± 9.04 | 41.2 ± 14.85 |
| Gender(Participants) | Part 1: Cohort 1 | Part 1: Cohort 2 | Part 1: Cohort 3 | Part 1: Cohort 4 | Part 1: Cohort 5 | Part 2: Cohort A | Part 2: Cohort B | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 6 | 0 | 0 | 0 | 20 | 20 | 46 |
| Male | 6 | 0 | 6 | 6 | 6 | 0 | 0 | 24 |
The record gives a start of Nov 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 7 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab